102 publications
| Name | Date | Type | Actions |
|---|---|---|---|
[VIDEO ]Présentation des résultats 2020 - french Présentation analystes & investisseurs - 1er avril 2021 |
01/04/2021 | Annual Report | |
[VIDEO] Présentation des résultats semestriels 2021 - french Présentation analystes & investisseurs - 29 juillet 2021 |
29/07/2021 | Half Year Report | |
[Video] Présentation des résultats semestriels 2022 - french Présentation analystes & investisseurs - 15 septembre 2022 |
29/07/2021 | Half Year Report | |
2013 annual results SFAF meeting March 13, 2014 |
18/03/2014 | Annual Report | |
2013 growth driven by reference products Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements. |
12/03/2014 | Public releases | |
2014 First half Results 2014 Half year results |
31/07/2014 | Half Year Report | |
20145 calendar of financial communication December 15, 2014 (Lure, France) – Vétoquinol published its calendar of financial communication for 2015. |
15/12/2014 | Agenda | |
2020 annual results 2020 sales: €427.5m (up 8.0% as reported)
EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m
|
01/04/2021 | Public releases | |
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” |
21/01/2021 | Public releases | |
2020 Universal registration document 2020 universal registration document including the Annual Financial Report |
28/04/2021 | Reference document |